10-Q: Shattuck Labs Reports Q1 2026 Financials, Advances SL-325 Trial

Shattuck Labs, Inc. filed its Q1 2026 10-Q, detailing a net loss of $14.8 million and continued progress in its SL-325 clinical trial, with cash reserves projected to fund operations into 2029.

Summary

• Shattuck Labs, Inc. reported a net loss of $14.8 million for the first quarter ended March 31, 2026, compared to a net loss of $13.7 million for the same period in 2025.
• Research and development expenses increased by 10.4% to $10.9 million, primarily due to advancing the SL-325 program into clinical development and increased personnel costs.
• General and administrative expenses remained relatively stable at $4.6 million.
• The company had $90.4 million in cash and cash equivalents as of March 31, 2026, which management believes is sufficient to fund operations for at least the next twelve months.
• Shattuck Labs expects to complete its Phase 1 clinical trial for SL-325 in healthy volunteers in the second quarter of 2026 and initiate a Phase 2 trial for Crohn's Disease in the third quarter of 2026.
• The company has an accumulated deficit of $445.3 million as of March 31, 2026.
• Shattuck Labs entered into a sales agreement in January 2026 to offer and sell up to $75.0 million of its common stock through an at-the-market offering facility.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the increased net loss, rising R&D expenses without revenue, and the continued reliance on external financing, despite positive cash flow from financing activities and progress in clinical trials.

Positives

• Cash and cash equivalents increased to $90.4 million as of March 31, 2026, from $54.2 million as of December 31, 2025.
• The company successfully raised $21.4 million through its at-the-market offering facility in the first quarter of 2026.
• Management believes current cash reserves are sufficient to fund projected operations for at least the next twelve months.
• The Phase 1 clinical trial for SL-325 is expected to be completed in Q2 2026, with a Phase 2 trial for Crohn's Disease planned for Q3 2026, indicating continued progress in drug development.
• The company has potential future milestone payments of up to $86.0 million and tiered royalties from the Kayak Therapeutics agreement.

Negatives

• The company reported a net loss of $14.8 million for the quarter, an increase from the prior year's $13.7 million loss.
• An accumulated deficit of $445.3 million as of March 31, 2026, highlights the company's long-standing unprofitability.
• Research and development expenses increased by 10.4% to $10.9 million, reflecting ongoing investment without current revenue generation.
• The company is highly dependent on future financing, including equity and debt financings, and collaborations, with no assurance of availability on acceptable terms.
• The company has not generated significant product revenue and does not expect to until its product candidates are successfully developed, approved, and sold, which is expected to take several years.

Risks

• The company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $445.3 million as of March 31, 2026.
• Adequate additional funding may not be available to the Company on acceptable terms, or at all, and failure to raise funds as and when needed could negatively impact the Company's financial condition and ability to pursue its clinical operations.
• The timing, progress, and expected results of nonclinical studies and clinical trials are subject to substantial risks and uncertainties.
• The company is highly dependent on a limited number of contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), which could lead to adverse effects from significant interruptions in their services.
• Global macroeconomic conditions, including inflation, slower growth, and geopolitical instability, could negatively affect future operations.
• The company may never succeed in achieving regulatory approval for its product candidates.
• There is a risk of potential cross-binding of anti-drug antibodies (ADAs) generated against TL1A antibodies to other therapeutic agents, impacting efficacy.

Future Outlook

The company anticipates incurring additional losses and negative cash flows from operations until it can generate significant sales of its product candidates. Management believes its current cash and cash equivalents are sufficient to fund projected operations for at least the next twelve months. Future funding requirements will depend on various factors including the progress of discovery, nonclinical, and clinical trials, manufacturing costs, intellectual property protection, and potential commercialization activities. The company expects to continue seeking additional capital through equity offerings, debt financings, or collaborations.

Management Comments

• Management believes that the Company's cash and cash equivalents of $90.4 million as of March 31, 2026 are sufficient to fund projected operations of the Company for at least the next twelve months following the date these financial statements are issued.
• We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities.
• We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, if ever, which we expect will take several years.
• We believe that our cash and cash equivalents as of March 31, 2026, and assuming the full exercise of the outstanding common stock warrants, are sufficient to fund projected operations into 2029.

Industry Context

StockSavvy.ai notes that Shattuck Labs operates in the highly competitive and capital-intensive biotechnology sector, where significant investment in research and development is required with no guarantee of success. The company's focus on the DR3/TL1A pathway for inflammatory and immune-mediated diseases places it in a therapeutic area with substantial unmet medical needs, but also with emerging competition from other companies developing therapies targeting similar pathways.

Comparison to Industry Standards

• Shattuck Labs' net loss of $14.8 million for the quarter is consistent with early-stage biotechnology companies that are heavily investing in R&D without current revenue.
• The company's cash burn rate of approximately $13.4 million for the quarter is within the typical range for clinical-stage biotechs, but its ability to fund operations into 2029 (assuming warrant exercises) is a key factor for investors.
• The development of SL-325, a DR3 antagonist, is positioned against TL1A blocking antibodies. Competitors like Pfizer (with PF-06651600), Merck (with MK-8283), and others are also developing TL1A inhibitors, indicating a race to market in this therapeutic space.
• The company's strategy to avoid immune complex formation, a known issue with TL1A antibodies (e.g., afimkibart, tulisokibart, duvakitug), by targeting DR3 directly, is a key differentiator that aligns with industry efforts to improve drug safety and efficacy profiles.

Legal Proceedings

• As of March 31, 2026, the Company was not aware of any existing, pending, or threatened legal actions that would have a material impact on its financial position, results of operations, or cash flows.

Related Party Transactions

• In August 2025, Shattuck Labs granted Kayak Therapeutics, Inc. an exclusive license to its oncology-focused TRIM7 program, receiving preferred stock valued at $1.0 million, recognized as license revenue.
• Shattuck Labs subleases lab space, office space, and lab equipment to Kayak for one year for $0.3 million. Payments received for the three months ended March 31, 2026 were $0.1 million and reduced R&D expenses.
• An officer of Shattuck Labs was elected to the board of directors of Kayak in November 2025, making Kayak a related party.

Stakeholder Impact

• Shareholders may experience dilution if additional equity financing is pursued.
• Creditors and debt holders are subject to the company's ability to manage its cash burn and secure future funding.
• Employees are critical to the company's R&D efforts, and retention of key personnel is highlighted as a factor for future success.
• Suppliers and CDMOs/CROs are essential for clinical trial material manufacturing and research activities, with potential risks associated with supply chain disruptions.

Next Steps

• Complete Phase 1 clinical trial for SL-325 in healthy volunteers in the second quarter of 2026.
• Initiate a randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn's Disease in the third quarter of 2026.
• Continue to seek private or public equity and debt financing, and/or additional collaborations with third parties to meet capital requirements.
• Continue to develop and defend its intellectual property portfolio.

Key Dates

Recommendation

Shattuck Labs shows promising clinical development progress with SL-325 and a strategic approach to differentiate from competitors in the DR3/TL1A pathway. However, the increased net loss, rising R&D costs without revenue, and continued reliance on future financing present significant risks. The company's cash runway, assuming warrant exercises, extends into 2029, providing some buffer. Given the balance of potential upside from clinical success against the financial risks and competitive landscape, a 'hold' recommendation is appropriate for seasoned investors, pending further clinical data and clarity on financing.

Keywords

Shattuck Labs, SEC Filing, 10-Q, Biotechnology, Drug Development, Clinical Trials, SL-325, DR3 Antagonist, TL1A Pathway, Inflammatory Diseases, Crohn's Disease, Financial Results, Net Loss, Cash Burn, Funding Needs